- Motley Fool•2 days ago
PCSK-9 inhibitors lowered LDL-C by roughly 60% in clinical trials, but do their costs far outweigh their benefits?
- Benzinga•2 days ago
After a placid summer seldom interrupted by news of note, word comes down from Wyoming on Friday as Fed Chair Janet Yellen speaks. Speculation centers around what Yellen could say about potential rate ...
- Barrons.com•2 days ago
Amgen (AMGN:Nasdaq) Gabelli & Co. ($170.23, Aug. 26, 2016) We are initiating our coverage on Amgen with a Hold recommendation and a 2017 private market value of $190 per share. The revenue of Amgen’s legacy products is expected to decline at 4% compounded annualized growth rate (CAGR) through 2020 driven by biosimilar or generic erosion to Epogen, Aranesp, Neupogen, Neulasta and Sensipar. Amgen’s revenue from growth products is expected to grow at 16% CAGR, mainly driven by Xgeva/Prolia, Kyprolis and Repatha.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||168.00 x 200|
|Ask||175.01 x 300|
|Day's Range||169.76 - 172.99|
|52wk Range||130.09 - 176.64|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.60|
|Avg Vol (3m)||2,907,642|
|Dividend & Yield||4.00 (2.33%)|